维普中文期刊产品整合服务
19篇 您的检索式:作者名="Marshall PC"
    题名 作者 年代 出处 被引量
1Transfusion requirements in critical care: a pilot study显示文摘Hebert PC Wells G Marshall J 1995JAMA1995,273,:1
2Transfusion requirements in critical care:a pilot study显示文摘Hebert PC Wells G Marshall J 1995JAMA1995,273,18:1
3Serizurs and cerebral infarction in the full newborn显示文摘Levy SR Abroms IF Marshall PC 1985Ann Neurol1985,17,:1
4Symptomatic trigeminal neuralgia in a 5- year-old child 显示文摘Marshall PC Rosman NP 1977Pediatrics1977,60,3:1
5Safety and immu- nogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-con- trolled clinical trial显示文摘Marshall HS Richmond PC Nissen MD 2012Pediatr Infect Dis J2012,31,10:1
6Safety and immunogenielty of a meningoeoeeal B bivalent rLP2086 vac- cine in healthy toddlers aged 18-36 months, a phase 1 ran- domized-controlled clinical trial 显示文摘Marshall HS Richmond PC Nissen MD 2012Pediatr Infect Dis J2012,31,:1
7Safety and im- munogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-con- trolled clinical trial 显示文摘Marshall HS Richmond PC Nissen MD 2012Pediatr Infect Dis J2012,31,10:1
8A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults:results of a randomised,controlled,dose-escalation phase Ⅰ trial显示文摘Richmond PC Nissen MD Marshall HS 2012Vaccine2012,30,43:1
9Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months:a phase Ⅰ randomizedcontrolled clinical trial显示文摘Marshall HS Richmond PC Nissen MD 2012Pediatr Infect Dis J2012,31,10:1
10Safety,immunogenicity,and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents:a randomised,single-blind,placebo-controlled,phase 2 trial显示文摘Richmond PC Marshall HS Nissen MD 2012Lancet Infect Dis2012,12,8:1
11Transfusion requirements in critical care : A pilot study显示文摘Hebert PC Wells G Marshall J 1993JAMA1993,273,:1
12A phase 2 openlabel safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults显示文摘Marshall HS Richmond PC Nissen MD 2013Vaccine2013,31,12:1
13Safety and irrgramogenicity of a meningococcal B bivalent rLg2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial 显示文摘Marshall HS Richmond PC Nissen MD 2012Pediatr Infect Disease J2012,31,10:1
14Safety, immunogenicity, and tohrability of mertingococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 tfial显示文摘Richmond PC Marshall HS Nissen MD 2012Lancet Infect Dis2012,12,8:1
15A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults : results of a randomised, controlled, dose-escalation phase 1 trial显示文摘RichmondI PC Nissen MD Marshall HS 2012Vaccine2012,30,43:1
16A phase 2 open-label safety and immunogenieity study of a meningococeal B bivalent rLP2086 vaccine in healthy adults 显示文摘Marshal HS Richmond PC Nissen MD 2013Vaccine2013,31,12:1
17A single-cell genome for Thiovulum sp显示文摘Marshall I P Blainey PC Spormann AM 2012Applied and Environmental Microbiology2012,78,24:1
18Seizures and cerebral infarc- tion in the full newborn 显示文摘Levy SR Abroms IF Marshall PC 1985Ann Neurol1985,17,:1
19受伤患儿合并致死性出血时的输血比率和输注不足情况显示文摘目的评估血浆和血小板输注比率和输注不足对外伤后致死性出血患儿的影响。设计对儿童大量输血流行病学和预后(MATIC)研究数据集进行二次分析,为一项针对致死性出血患儿的前瞻性观察性研究。场所美国、加拿大和意大利的24家儿童医院。对象0~17岁的受伤儿童,在6 h内接受超过40 mL/kg的血制品总量,或根据大量输血方案(massive transfusion protocol,MTP)输血。干预措施/暴露记录出血事件中输注的体重校正后血制品容量。分析血浆/红细胞比率(血浆/红细胞体重校正容量,单位mL/kg)和血小板/红细胞比率(血小板/红细胞体重校正容量,单位mL/kg)。血浆输注不足按红细胞(mL/kg)-血浆(mL/kg)计算;血小板输注不足按红细胞(mL/kg)-血小板(mL/kg)计算。测量方法与主要结果共分析191例患儿,中位年龄(四分位数范围)10(5~15)岁,男性患儿占61%,钝性损伤占61%,中位创伤严重度评分为29(24~38)分。在校正小儿死亡风险(PRISM)评分、心脏骤停、血管活性药物使用和钝性损伤机制后,相比于低血浆/红细胞比率,高血浆/红细胞比率(>1∶2)与6 h存活率改善有关(OR=0.12,95%CI 0.03~0.52,P=0.004)。血小板/红细胞比率与存活率无关。在校正年龄、PRISM评分、心脏骤停和损伤机制后,血浆输注不足量越大,患儿6 h和24 h病死率越高(每10 mL/kg血浆输注不足可导致6 h和24 h病死风险分别增加10%和20%,P值分别为0.04和0.01);血小板输注不足量越大,患儿24 h病死率越高(每10 mL/kg血小板输注不足可致患儿24 h病死风险增加10%,P=0.02)。结论研究结果提示,受伤患儿平衡复苏可能会改善早期存活率。需要多中心临床试验来评估临床医生是否应将设定输血比率和输血不足阈值作为最佳儿童止血复苏治疗的一部分。Spinella PC Leonard JC Marshall C 方伯梁(译) 钱素云(校) 2022中国小儿急救医学2022,29,7:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费